Bladder Cancer Coverage from Every Angle

Petros Grivas, MD, PhD, on Update on Treatment With Sacituzumab Govitecan-hziy and Pembrolizumab in Urothelial Cancer

Posted: Wednesday, March 23, 2022

Petros Grivas, MD, PhD, of the University of Washington and Fred Hutchinson Cancer Research Center, discusses the potential role of sacituzumab govitecan-hziy in combination with pembrolizumab in patients with metastatic urothelial cancer who experienced disease progression after platinum-based regimens.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.